Detection of Neurodegenerative Disease

Abstract

Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided.

1 - 18 . (canceled) 
     
     
         19 . A purified antibody that binds to TDP-43 or fragments thereof in ubiquitin-positive, tau- and α-synuclein-negative inclusions in subjects having Type 1 ubiquitin-positive frontotemporal lobar degeneration. 
     
     
         20 . A purified antibody that binds to TDP-43 or fragments thereof in ubiquitin-positive, tau- and α-synuclein-negative inclusions in subjects having Type 2 ubiquitin-positive frontotemporal lobar degeneration. 
     
     
         21 - 30 . (canceled)